REN and diabetic kidney disease: The growing evidence for the nephroprotective effects of SGLT2i beyond diabetic nephropathy has catalysed their integration into clinical practice in the last few years, particularly as an adjunctive therapy for patients with glomerular diseases and persistent proteinuria despite renin–angiotensin therapy or diuretics.